- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001715
Evaluation of Patients With Blood Disorders
Evaluation of Hematologic Patients - Training Protocol
The Hematology Service provides hematology consultations for patients at the Clinical Center and participates in the training of hematology fellows. Patients with a broad range of hematologic disorders must be available in order for the senior staff of the Service to maintain clinical expertise and to provide the breadth of experience necessary for the fellowship program. The purpose of this protocol is to meet these needs by allowing the Hematology Service to see patients with a spectrum of hematologic diseases not studied on existing research protocols at the NIH. These patients will be evaluated over the course of several outpatient visits and returned to the care of their referring physicians.This study was developed to evaluate and possibly treat patients with blood disorders. The Hematology Service of the National Institutes of Health is responsible for the care of patients participating in research studies. In addition the Hematology Service also provides consultation for small groups of patients with blood disorders that have not been diagnosed or that may need special testing.
This study will also provide doctors at the NIH the opportunity to learn more about a wide range of blood disorders and conditions. Patients participating in this study will be evaluated over the course of several outpatient visits and will continue to be cared for by their regular physician.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
The patient must have or be suspected of having a blood disorder.
The patient must be clinically stable enough for outpatient evaluation.
The patients must be referred from a physician outside the NIH who will continue to provide the patient's primary medical care.
EXCLUSION CRITERIA:
Inability of patient, parent or legal gaurdian to provide informed consent.
Study Plan
How is the study designed?
Collaborators and Investigators
Investigators
- Principal Investigator: Jay N Lozier, M.D., National Institutes of Health Clinical Center (CC)
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 980090
- 98-CC-0090
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Disease
-
Universitaire Ziekenhuizen KU LeuvenB. Braun Medical SA; RITA Medical SystemsCompleted
-
Nelson ChaoNational Center for Advancing Translational Sciences (NCATS); Mereo BioPharmaWithdrawnHematologic MalignancyUnited States
-
Memorial Sloan Kettering Cancer CenterMillennium: The Takeda Oncology CompanyCompletedMyeloid Hematologic Malignancy | Lymphoid Hematologic MalignancyUnited States
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
Dana-Farber Cancer InstituteTerminated
-
Memorial Sloan Kettering Cancer CenterRecruitingHematologic Malignancy | Graft Versus Host Disease | Graft Vs Host DiseaseUnited States
-
Universitaire Ziekenhuizen KU LeuvenLeuvens Kanker InstituutCompletedHematologic Disease | Oncology, MedicalBelgium
-
Nantes University HospitalRecruitingHematologic Malignancy | Graft Versus Host DiseaseFrance
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Institutes of Health (NIH)CompletedHematologic Malignancies | Graft-Versus-Host DiseaseUnited States
-
National Research Center for Hematology, RussiaNot yet recruitingHematologic Malignancy | Graft Versus Host Disease | Cyclophosphamide Adverse Reaction